Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.
Department of Haematopathology, Nanakali Haemato-Oncology Teaching Centre, Erbil, Iraq.
PLoS One. 2018 Apr 12;13(4):e0195629. doi: 10.1371/journal.pone.0195629. eCollection 2018.
Hodgkin's Lymphoma (HL) reveals variable epidemiological and clinico-pathological features in different geographical locations. In this retrospective study, we aimed to assess the epidemiological and clinic-pathological features, and outcome of HL patients treated at one hemato-oncology centre in Erbil, northern Iraq. Medical records of 103 HL patients treated over more than six years were reviewed. Treatment outcome was evaluated by measuring the 5-year overall and progression-free survival rates. The median age of patients was 23 years, children up to 17 years constituted 31.1%, and male to female ratio was 1:1.05. The majority (96.1%) of patients presented with lymphadenopathy. Nodular sclerosis subtype was the mostly encountered histologic type (48.5%); about half of the patients (49.5%) had stage II disease. Relapse occurred in 20 patients; the 5-year overall survival for children was better (89%) compared to adult patients (79%). The associated risk features found to have adverse effects on the survival, however, only high LDH level and presence of B-symptoms at presentation showed significant correlation. The epidemiological and clinical characteristics of HL in our locality followed the pattern in the western world. The 5-year overall and progression-free survivals were far below the international rates, a matter which may necessitate a revision to HL treatment strategy at our centre.
霍奇金淋巴瘤（HL）在不同地理位置表现出不同的流行病学和临床病理特征。在这项回顾性研究中，我们旨在评估在伊拉克北部埃尔比勒的一个血液肿瘤科中心治疗的 HL 患者的流行病学、临床病理特征和结局。我们回顾了超过六年时间内接受治疗的 103 例 HL 患者的病历。通过测量 5 年总生存率和无进展生存率来评估治疗结局。患者的中位年龄为 23 岁，17 岁以下的儿童占 31.1%，男女比例为 1:1.05。大多数（96.1%）患者表现为淋巴结病。结节性硬化型是最常见的组织学类型（48.5%）；约一半的患者（49.5%）处于 II 期疾病。20 例患者出现复发；儿童的 5 年总生存率（89%）优于成年患者（79%）。然而，只有高乳酸脱氢酶水平和出现 B 症状与生存相关，被发现是对生存有不利影响的相关风险特征。我们当地的 HL 流行病学和临床特征与西方世界的模式一致。5 年总生存率和无进展生存率远低于国际水平，这可能需要我们中心修订 HL 治疗策略。
